within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF07_Deucravacitinib;

model Deucravacitinib
  extends Pharmacolibrary.Drugs.ATC.L.L04AF07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AF07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis in adults. It is approved and commercially available in several countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after single and repeated oral administration.</p><h4>References</h4><ol><li><p>Truong, TM, Pathak, GN, Singal, A, Taranto, V, &amp; Rao, BK (2024). Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. <i>The Annals of pharmacotherapy</i> 58(4) 416–427. DOI:<a href=\"https://doi.org/10.1177/10600280231153863\">10.1177/10600280231153863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37341177/\">https://pubmed.ncbi.nlm.nih.gov/37341177</a></p></li><li><p>Chimalakonda, A, Burke, J, Cheng, L, Catlett, I, Tagen, M, Zhao, Q, Patel, A, Shen, J, Girgis, IG, Banerjee, S, &amp; Throup, J (2021). Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. <i>Dermatology and therapy</i> 11(5) 1763–1776. DOI:<a href=\"https://doi.org/10.1007/s13555-021-00596-8\">10.1007/s13555-021-00596-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34471993/\">https://pubmed.ncbi.nlm.nih.gov/34471993</a></p></li><li><p>Eichinger, JM, Shan, DM, Greenzaid, JD, Anakwenze, L, &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 249–262. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2335310\">10.1080/17425255.2024.2335310</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38529623/\">https://pubmed.ncbi.nlm.nih.gov/38529623</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Deucravacitinib;
